recurrent glioblastoma
Showing 26 - 50 of 97
Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligoastrocytoma, Recurrent Anaplastic Oligodendroglioma Trial in Duarte
Withdrawn
- Recurrent Anaplastic Astrocytoma
- +7 more
- Neural Stem Cells-expressing CRAd-S-pk7
- Resection
- (no location specified)
Nov 22, 2022
Glioblastoma, Recurrent Glioblastoma, GBM Trial in Boston (MN-166, Temozolomide)
Active, not recruiting
- Glioblastoma
- +3 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Nov 16, 2022
Intracranial Tumor, Low Grade Glioma, Recurrent Glioblastoma Trial in San Francisco (F-18 Fluoroethyltyrosine (FET), Positron
Recruiting
- Intracranial Neoplasm
- +4 more
- F-18 Fluoroethyltyrosine (FET)
- Positron Emission Tomography (PET)
-
San Francisco, CaliforniaUniversity of California, San Francisco
Nov 7, 2022
Recurrent Glioblastoma Trial in Beijing (Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous
Not yet recruiting
- Recurrent Glioblastoma
- Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes.
-
Beijing, Beijing, ChinaBeijing Tiantan Hospital
Oct 10, 2022
Recurrent Glioblastoma Trial in Miami (Intensity Modulated Proton Therapy (IMPT), Bevacizumab)
Recruiting
- Recurrent Glioblastoma
- Intensity Modulated Proton Therapy (IMPT)
- Bevacizumab
-
Miami, FloridaUniversity of Miami
Sep 30, 2022
Glioblastoma, Recurrent Glioblastoma Trial in Iowa City (Static Magnetic and Electric (sBE) device, Lomustine, Bevacizumab)
Not yet recruiting
- Glioblastoma
- Recurrent Glioblastoma
- Static Magnetic and Electric (sBE) device
- +2 more
-
Iowa City, IowaUniversity of Iowa Hospitals & Clinics
Sep 20, 2022
Recurrent Glioblastoma Trial in Zhengzhou (Tislelizumab plus Bevacizumab)
Recruiting
- Recurrent Glioblastoma
- Tislelizumab plus Bevacizumab
-
Zhengzhou, Henan, ChinaHenan Provincial People's Hospital
Sep 11, 2022
Gliosarcoma, Recurrent Glioblastoma Trial in Chicago (Laboratory Biomarker Analysis, Pharmacological Study, Targeted Molecular
Completed
- Gliosarcoma
- Recurrent Glioblastoma
- Laboratory Biomarker Analysis
- +2 more
-
Chicago, IllinoisNorthwestern University
Aug 5, 2022
Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype Trial in Chicago (drug, other, radiation)
Recruiting
- Astrocytoma
- +4 more
- Mycophenolate Mofetil
- +3 more
-
Chicago, IllinoisNorthwestern University
Aug 22, 2022
Diffuse Intrinsic Pontine Glioma, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma Trial in Switzerland, United States
Active, not recruiting
- Diffuse Intrinsic Pontine Glioma
- +4 more
- Fimepinostat
- Therapeutic Conventional Surgery
-
Los Angeles, California
- +18 more
Aug 16, 2022
Glioblastoma, Malignant Glioma, Recurrent Glioblastoma Trial in Worldwide (biological, drug, other)
Recruiting
- Glioblastoma
- +5 more
- Ipilimumab
- +4 more
-
Birmingham, Alabama
- +19 more
Aug 16, 2022
Recurrent Glioblastoma Trial in Heidelberg, Nedlands (TTAC-0001 and pembrolizumab combination)
Active, not recruiting
- Recurrent Glioblastoma
- TTAC-0001 and pembrolizumab combination
-
Heidelberg, Victoria, Australia
- +1 more
Aug 15, 2022
Glioblastoma Multiforme, Recurrent Glioblastoma Trial in United States (TheraSphere GBM)
Recruiting
- Glioblastoma Multiforme
- Recurrent Glioblastoma
- TheraSphere GBM
-
San Francisco, California
- +4 more
Aug 15, 2022
IDH Family Wildtype, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma Trial in Houston (Laser Interstitial Thermal
Terminated
- IDH Family Wildtype
- +2 more
- Laser Interstitial Thermal Therapy
- Lomustine
-
Houston, TexasM D Anderson Cancer Center
Jul 14, 2022
Recurrent Glioblastoma, Recurrent Astrocytoma, Recurrent Oligodendroglioma Trial in Oklahoma City (Niraparib)
Recruiting
- Recurrent Glioblastoma
- +3 more
-
Oklahoma City, OklahomaStephenson Cancer Center
Jul 20, 2022
Glioblastoma, Recurrent Glioblastoma Trial in Boston (Pembrolizumab, Olaparib, Temozolomide)
Not yet recruiting
- Glioblastoma
- Recurrent Glioblastoma
- Pembrolizumab
- +2 more
-
Boston, Massachusetts
- +2 more
Jul 14, 2022
Glioblastoma, Recurrent Glioblastoma, GBM Trial in Santa Monica (Radiation: Intra-operative Radiation Therapy - IORT,
Recruiting
- Glioblastoma
- +3 more
- Radiation: Intra-operative Radiation Therapy - IORT
- +2 more
-
Santa Monica, CaliforniaProvidence Saint John's Health Center
Jul 14, 2022
Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV Trial in Ann Arbor (drug, radiation, procedure)
Recruiting
- Recurrent Glioblastoma
- +5 more
- Mycophenolate Mofetil
- +3 more
-
Ann Arbor, MichiganUniversity of Michigan Rogel Cancer Center
Jul 7, 2022
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma Trial in United States (other, drug, procedure)
Active, not recruiting
- Anaplastic Astrocytoma
- +6 more
- Laboratory Biomarker Analysis
- +4 more
-
Los Angeles, California
- +11 more
Jul 1, 2022
Recurrent Glioblastoma Trial in Beijing (ASC40 tablets, Placebo tablets, Bevacizumab)
Recruiting
- Recurrent Glioblastoma
- ASC40 tablets
- +2 more
-
Beijing, Beijing, ChinaBeijing Tiantan Hospital,Capital Medical University
Jun 28, 2022
Recurrent Glioblastoma Trial in United States (Bevacizumab, Cediranib, Cediranib Maleate)
Active, not recruiting
- Recurrent Glioblastoma
- Bevacizumab
- +3 more
-
La Jolla, California
- +26 more
Jun 28, 2022
Glioblastoma, Recurrent Disease, Recurrent Glioblastoma Trial in Calgary (Afatinib, Dasatinib, Palbociclib)
Not yet recruiting
- Glioblastoma
- +2 more
- Afatinib
- +4 more
-
Calgary, Alberta, CanadaTom Baker Cancer Centre
Jun 24, 2022
Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligoastrocytoma, Recurrent Anaplastic Oligodendroglioma Trial in Duarte
Active, not recruiting
- Recurrent Anaplastic Astrocytoma
- +6 more
- Carboxylesterase-expressing Allogeneic Neural Stem Cells
- +4 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jun 7, 2022